vTv Therapeutics annual operating margin
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2024
vTv Therapeutics's operating margin was −2,377.58% for fiscal 2024.
View full vTv Therapeutics company overview| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2024 | 2024-12-31 | −2,377.58% | −1260.63 pp |
| 2022 | 2022-12-31 | −1,116.95% | −576.07 pp |
| 2021 | 2021-12-31 | −540.87% | −356.09 pp |
| 2020 | 2020-12-31 | −184.78% | +571.08 pp |
| 2019 | 2019-12-31 | −755.86% | −596.43 pp |
| 2018 | 2018-12-31 | −159.43% | +17257.06 pp |
| 2017 | 2017-12-31 | −17,416.49% | −8738.26 pp |
| 2016 | 2016-12-31 | −8,678.23% | −1329.10 pp |
| 2015 | 2015-12-31 | −7,349.13% | −5483.61 pp |
| 2014 | 2014-12-31 | −1,865.53% | +1805.89 pp |
| 2013 | 2013-12-31 | −3,671.41% | — |
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q1 2026 | 2026-03-31 | 63.15% | +44807.59 pp |
| Q4 2024 | 2024-12-31 | −28,776.47% | −28452.42 pp |
| Q1 2024 | 2024-03-31 | −562.70% | +122870.63 pp |
| Q4 2022 | 2022-12-31 | −70,477.78% | −70424.34 pp |
| Q2 2022 | 2022-06-30 | −44,744.44% | +7144.44 pp |
| Q1 2022 | 2022-03-31 | −324.05% | +109.59 pp |
| Q4 2021 | 2021-12-31 | −123,433.33% | −123461.93 pp |
| Q3 2021 | 2021-09-30 | −53.43% | +40403.71 pp |
| Q2 2021 | 2021-06-30 | −51,888.89% | +31186.11 pp |
| Q1 2021 | 2021-03-31 | −433.64% | +90823.51 pp |
| Q4 2020 | 2020-12-31 | 28.60% | +67841.10 pp |
| Q3 2020 | 2020-09-30 | −40,457.14% | −40195.00 pp |
| Q1 2020 | 2020-03-31 | −83,075.00% | −82609.53 pp |
| Q4 2019 | 2019-12-31 | −91,257.14% | −91249.38 pp |
| Q3 2019 | 2019-09-30 | −67,812.50% | −67768.62 pp |
| Q2 2019 | 2019-06-30 | −262.14% | +96.04 pp |
| Q1 2019 | 2019-03-31 | −465.47% | −22.93 pp |
| Q4 2018 | 2018-12-31 | −7.76% | +5473.78 pp |
| Q3 2018 | 2018-09-30 | −43.88% | +76896.12 pp |
| Q2 2018 | 2018-06-30 | −358.19% | +96680.27 pp |
| Q1 2018 | 2018-03-31 | −442.54% | +45404.13 pp |
| Q4 2017 | 2017-12-31 | −5,481.55% | +29552.67 pp |
| Q3 2017 | 2017-09-30 | −76,940.00% | −41340.00 pp |
| Q2 2017 | 2017-06-30 | −97,038.46% | −88995.05 pp |
| Q1 2017 | 2017-03-31 | −45,846.67% | −42245.60 pp |
| Q4 2016 | 2016-12-31 | −35,034.21% | −30126.69 pp |
| Q3 2016 | 2016-09-30 | −35,600.00% | −28501.50 pp |
| Q2 2016 | 2016-06-30 | −8,043.41% | −871.59 pp |
| Q1 2016 | 2016-03-31 | −3,601.06% | +15840.94 pp |
| Q4 2015 | 2015-12-31 | −4,907.52% | −3527.52 pp |
| Q3 2015 | 2015-09-30 | −7,098.50% | — |
| Q2 2015 | 2015-06-30 | −7,171.82% | — |
| Q1 2015 | 2015-03-31 | −19,442.00% | — |
| Q3 2014 | 2014-09-30 | −1,380.00% | — |
Over the last five reported fiscal years, vTv Therapeutics's operating margin decreased from −159.43% to −2,377.58%, a change of −2218.15 percentage points. The latest reported quarter, Q1 2026, shows 63.15%.
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review vTv Therapeutics filings at SEC.gov ↗